Image pharmaphorum Editor Future of Generics The Falsified Medicines Directive – truly an opportunity for... Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’. Views & Analysis Changing the shape of healthcare Kris Sterkens, company group chairman of Janssen EMEA, explains why pharma needs to be part of the solution. News FDA expands Keytruda approval for first-line NSCLC treatment Cancer drug Keytruda can now be used as a first-line treatment for patients with stage three non-small cell lung cancer (NSCLC), whose treatment options are limited. Views & Analysis Does your brand need behavioural science? Behavioural science has become a buzzword for pharma. Why? Because behaviour is a barrier to meeting brand objectives. Load more results
Future of Generics The Falsified Medicines Directive – truly an opportunity for... Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’.
Views & Analysis Changing the shape of healthcare Kris Sterkens, company group chairman of Janssen EMEA, explains why pharma needs to be part of the solution.
News FDA expands Keytruda approval for first-line NSCLC treatment Cancer drug Keytruda can now be used as a first-line treatment for patients with stage three non-small cell lung cancer (NSCLC), whose treatment options are limited.
Views & Analysis Does your brand need behavioural science? Behavioural science has become a buzzword for pharma. Why? Because behaviour is a barrier to meeting brand objectives.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
